Vedanta Biosciences reported that an independent data monitoring committee has recommended the Phase III RESTORATiVE303 trial of VE303 continue without modification following a prespecified interim analysis, with the DMC determining that efficacy exceeded the futility threshold and no new safety signals had emerged.
RESTORATiVE303 is a randomized, double-blind, placebo-controlled, multinational Phase III trial enrolling patients at high risk for recurrent Clostridioides difficile infection (CDI) across more than 150 sites in approximately 20 countries, with participants randomized 2:1 to a 14-day course of VE303 or placebo.
The interim analysis was triggered when 50% of planned enrollees had reached the Week 8 primary efficacy timepoint, which is the CDI recurrence rate at that mark. No numerical efficacy or safety data were disclosed; the DMC's mandate in a blinded trial is limited to assessing whether accumulating data fall within prespecified statistical boundaries, and a continuation recommendation indicates the trial retains adequate power to detect the primary endpoint at protocol-defined sample size. The DMC reported no significant adverse events or new safety signals.
Vedanta anticipates completing enrollment in the second half of 2026, with a second interim analysis also planned for that period.
VE303 is a live biotherapeutic product consisting of a defined consortium of eight bacterial strains produced from pure, clonal cell banks — a manufacturing approach that bypasses donor fecal material entirely. In the Phase II CONSORTiUM study, high-dose VE303 achieved a 30.5% adjusted absolute risk reduction in CDI recurrence versus placebo, corresponding to a greater than 80% reduction in the odds of recurrence. The Phase III trial is intended to support a Biologics License Application to the FDA. VE303 holds Orphan Drug Designation (2017) and Fast Track Designation (2023).
Competitive context
The recurrent CDI prevention space now contains two FDA-approved microbiome-based live biotherapeutics: Vowst (fecal microbiota spores, live-brpk), approved in April 2023, and Rebyota (fecal microbiota, live-jslm), approved in November 2022. Both are donor-derived products — Vowst administered orally and Rebyota rectally — and both demonstrated reduced recurrence versus placebo in their pivotal trials. VE303's defined, non-donor-derived composition is its primary structural distinction from these approved competitors. Cross-trial comparisons are limited by differences in patient populations, prior CDI episode counts, qualifying antibiotic regimens, and endpoint definitions, so Phase II data for VE303 cannot be directly benchmarked against pivotal data for Vowst or Rebyota.
The CDI market also includes bezlotoxumab (Zinplava), a monoclonal antibody that neutralizes C. difficile toxin B and is administered as a single IV infusion adjunct during antibiotic therapy, and fidaxomicin (Dificid), the narrow-spectrum antibiotic that is guideline-preferred for recurrent CDI treatment and is itself part of the standard-of-care backdrop in RESTORATiVE303 — the trial enrolls a proportion of patients receiving fidaxomicin for their qualifying CDI episode. VE303 is positioned as a post-antibiotic microbiome restoration agent, complementary to rather than competitive with antibiotic treatment.
Spot something wrong? Report an issue with this article